Declaration of interests
CO received grants (paid to her institution) from Gilead Sciences, MSD, and ViiV Healthcare; received consulting fees for advisory boards and payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Bavarian Nordic, Gilead Sciences, GSK, MSD, and ViiV Healthcare; received support for attending meetings and/or travel from Bavarian Nordic, Gilead Sciences, and ViiV Healthcare; and is a governing council member of the International AIDS Society (unpaid). PJR received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Gilead Sciences and ViiV Healthcare. MH received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events, and support for attending meetings and/or travel from, and participated on advisory boards for, Gilead Sciences, Merck, and ViiV Healthcare. CG received consulting fees from Gilead Sciences, Merck, and ViiV Healthcare; and received payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, or educational events from Gilead Sciences and ViiV Healthcare. MHL received research grants (paid to his institution) from Gilead Sciences, and participated on advisory boards for Gilead Sciences and ViiV Healthcare. BT received consulting fees, payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events, and support for attending meetings and/or travel, from Gilead Sciences and ViiV Healthcare. TL received grants or contracts from AbbVie, Charité Berlin, Deutsche Leberstiftung, Gilead Sciences, GSK/ViiV Healthcare, Immuno Therapeutics Heidelberg, Janssen, Moderna, and MSD. MO received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Gilead Sciences; received support for attending meetings and/or travel from Gilead Sciences, Janssen, and ViiV Healthcare; participated on a data safety monitoring or advisory board for Gilead Sciences; and is an unpaid member of ASHM Board and Australian ARV Guidelines Committee. MB received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Gilead Sciences, GSK, and ViiV Healthcare; received support for attending meetings and/or travel from Gilead Sciences and ViiV Healthcare; and participated on data safety monitoring or advisory boards for Gilead Sciences, GSK, and ViiV Healthcare. JS received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Gilead Sciences, Merck, Thera, and ViiV Healthcare. MRa received consulting fees from Gilead Sciences, Shionogi, and ViiV Healthcare; and received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from AbbVie, Gilead Sciences, and ViiV Healthcare. SS received research grants and support for clinical trials (paid to her institution) from Janssen, Merck, and the South African Medical Research Council; received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from ViiV Healthcare; received support for attending meetings and/or travel from Merck; received a drug donation to her institution from ViiV Healthcare; and participated on an advisory board for AbbVie. KM received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from, and served on an advisory board for, Epividian, Gilead Sciences, Janssen, Merck, and ViiV Healthcare. H-CT received honoraria for a lecture at an international congress, and travel and registration support for attending an international meeting, from Gilead Sciences. JSB received research grants or contracts from Chem Bio Diagnostics, Gilead Sciences, and Moderna; and consulting fees and payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from AbbVie. XZ, KA, KP, NM, JMM-R, PS, and MRh are employees of Gilead Sciences and own employee stock grants. PC received research grants and payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from ViiV Healthcare; and consulting fees from Gilead Sciences, Merck, and ViiV Healthcare.
